Vered Stearns, Opeyemi A Jegede, Victor Tsu-Shih Chang, Todd C Skaar, Jeffrey L Berenberg, Ranveer Nand, Atif Shafqat, Nisha Lassi Jacobs, William Luginbuhl, Paul Gilman, Al B Benson, Judie R Goodman, Gary L Buchschacher, N Lynn Henry, Charles L Loprinzi, Patrick J Flynn, Edith P Mitchell, Michael Jordan Fisch, Joseph A Sparano, Lynne I Wagner
PURPOSE: Aromatase Inhibitor-Associated Musculoskeletal Symptoms (AIMSS) are common and frequently lead to AI discontinuation. Single nucleotide polymorphisms (SNPs) in candidate genes have been associated with AIMSS and AI discontinuation. E1Z11 is a prospective cohort study designed to validate associations between 10 SNPs and AI discontinuation due to AIMSS. PATIENTS AND METHODS: Postmenopausal women with stage I-III hormone receptor-positive breast cancer received anastrozole 1 mg daily and completed patient-reported outcomes (PRO) to assess AIMSS (Stanford Health Assessment Questionnaire; HAQ) at baseline, 3, 6, 9, and 12 months...
April 19, 2024: Clinical Cancer Research